Skip to main content

Table 1 Baseline Clinical Characteristics for all Patients Treated from 2003 to 2015

From: Overview of adjuvant radiotherapy on survival, failure pattern and toxicity in stage I to II endometrial carcinoma: a long-term multi-institutional analysis in China

 

Patients (N = 1048)

Total (n = 1048)

Endometrioid Adenocarcinoma (n = 973)

Nonendometrioid Carcinoma (n = 75)

p-value

Clinical Characteristic

No.

%

No.

%b

No.

%b

 

Age, years

      

0.129

 Mean

56.1

 

56.0

 

57.6

  

 Range

23–86

 

23–86

 

33–79

  

Lymphadenectomy

      

0.010

 No

319

30.4

306

31.4

13

17.3

 

 Yes

729

69.6

667

68.6

62

82.7

 

 Median Number.

21.0

 

21.0

 

18.0

 

0.009

 Range

1–65

 

1–65

 

1–42

  

Stage (FIGO 2009)

      

0.012

 IA

474

45.2

428

44.0

46

61.3

 

 IB

426

40.7

406

41.7

20

26.7

 

 II

148

14.1

139

14.3

9

12.0

 

Diameter

      

0.630

  < 2 cm

111

10.6

102

16.1

9

18.8

 

  ≥ 2 cm

571

54.5

532

83.9

39

81.3

 

 Missing

366

34.9

     

Gradea

 G1

327

33.6

327

33.6

/

/

 

 G2

447

45.9

447

45.9

/

/

 

 G3

191

19.7

191

19.7

/

/

 

 Missing

8

0.8

8

0.8

/

/

 

Myometrial invasion

      

0.012

  < 1/2

535

51.0

486

50.4

49

65.3

 

  ≥ 1/2

505

48.2

479

49.6

26

34.7

 

 Missing

8

0.8

     

Invasion of lower uterine segment

      

0.080

 No

746

71.2

686

70.5

60

80.0

 

 Yes

302

28.8

287

29.5

15

20.0

 

LVSI

      

0.601

 Present

173

16.5

159

16.3

14

18.7

 

 Absent

875

83.5

814

83.7

61

81.3

 

Chemotherapy

      

0.000

 No

820

78.2

786

80.8

34

45.3

 

 Yes

228

21.8

187

19.2

41

54.7

 
  1. Abbreviations: FIGO International Federation of Gynecology and Obstetrics, LVSI Lympho-vascular Space Invasion
  2. aonly for endometrioid adenocarcinoma
  3. bWhen compared between patients with endometrioid adenocarcinoma and nonendometrioid carcinoma, only the percnet of known numbers were calculated